Difference between revisions of "Team:SYSU-MEDICINE/Parts"

Line 369: Line 369:
 
             </span>
 
             </span>
 
             <br/>
 
             <br/>
             Marking protein: Luciferase-T2A-dTomato-T2A-hFTH (<a target="_blank" href="http://parts.igem.org/Part:BBa_K1993006" style="color:#00afd1">BBa_K1993006</a>)
+
             Marking protein: Luciferase-T2A-dTomato-T2A-hFTH (<a target="_blank" href="http://parts.igem.org/Part:BBa_K1993006" style="color:#00afd1">BBa_K1993006</a>)<br/>
 
             A multi-functional marking protein was constructed to locate our engineered MSCs. By constructing such a making protein, we improved the function of the original part (BBa_I712019) and the capacity of tracing cells in vivo and in vitro.
 
             A multi-functional marking protein was constructed to locate our engineered MSCs. By constructing such a making protein, we improved the function of the original part (BBa_I712019) and the capacity of tracing cells in vivo and in vitro.
 
             <br/>
 
             <br/>

Revision as of 18:49, 18 October 2016

Parts

Favorites


1.
Figure 8.1
Chemokine receptor: CCR7 (BBa_K1993001)
A series of chemokine receptors were constructed to enhance the homing ability of MSCs, in which CCR7 is one of them. Overexpressed in our engineered MSCs and guided by corresponding chemokine, CCR7 could improve our engineered MSCs targeting to the inflamed lesions.

2.
Figure 8.2
Marking protein: Luciferase-IRES-eGFP (BBa_K1993008)
Internal ribosome entry site (IRES) and enhanced GFP (eGFP) were fused to the C terminus of Luciferase to form the modified marking protein Luciferase-IRES-eGFP. By constructing such a making protein, we improved the function of the original part (BBa_I712019) and the capacity of tracing cells in vivo and in vitro.

3.
Figure 8.3
Marking protein: Luciferase-T2A-dTomato-T2A-hFTH (BBa_K1993006)
A multi-functional marking protein was constructed to locate our engineered MSCs. By constructing such a making protein, we improved the function of the original part (BBa_I712019) and the capacity of tracing cells in vivo and in vitro.
4.
Figure 8.4
Device: CXCR5-IRES-eGFP (BBa_K1993005)
Such a device was constructed to confirm our goals in the DTH (delayed type hypersensitivity) animal model. It could enhance the homing ability of cells and confirm the targeting capacity of cells.

5.
Figure 8.5
Device: CXCR4-T2A-Luciferase-IRES-eGFP(BBa_K1993009)
Such a device was constructed to confirm our goals in the IBD (inflammatory bowel disease) animal model. It could enhance the homing ability of cells and report cells in vivo and in vitro which helped us confirm whether our cells located to inflamed sites.

Parts List

1 Parts for Chemokine Receptors

Part Name Part Number Part Name Part Number
CXCR1 BBa_K1993002 CXCR5 BBa_K1993013
CXCR4 BBa_K1993003 CCR2 BBa_K1993012
CCR5 BBa_K1993004 CCR7 BBa_K1993001

2 Parts for Marking Proteins

Part Name Part Number Part Name Part Number
Luciferase (Renilla reniformis) BBa_K1993015 eGFP BBa_K1993017
Luciferase(Firefly Luciferase) BBa_K1993018 dTomato BBa_K1993020
Luciferase-IRES-eGFP BBa_K1993025 attB1-eGFP BBa_K1993024
Luciferase-T2A-dTomato-T2A-hFTH BBa_K1993026 hFTH BBa_K1993021
IRES-Luciferase-T2A-dTomato-T2A-hFTH BBa_K1993035 IRES-eGFP BBa_K1993034

3 Parts for Switch Plasmids

Part Name Part Number Part Name Part Number
pSMA BBa_K1993022 pSMA-eGFP BBa_K1993014

4 Parts for Composite Devices

Part Name Part Number
Luciferase-IRES-eGFP BBa_K1993008
Luciferase-T2A-dTomato-T2A-hFTH BBa_K1993006
CXCR4-IRES-eGFP BBa_K1993007
CXCR5-IRES-eGFP BBa_K1993005
CXCR4-T2A-Luciferase-IRES-eGFP BBa_K1993009
CXCR5-T2A-Luciferase-IRES-eGFP BBa_K1993010
CXCR4-IRES-Luciferase-T2A-dTomato-T2A-hFTH BBa_K1993011
IRES BBa_K1993016
T2A BBa_K1993019
attB2-IRES BBa_K1993023
CXCR4-IRES-eGFP BBa_K1993027
CXCR5-IRES-eGFP BBa_K1993028
CXCR4-T2A-Luciferase-IRES-eGFP BBa_K1993029
CXCR5-T2A-Luciferase-IRES-eGFP BBa_K1993030
CXCR4-IRES-Luciferase-T2A-dTomato-T2A-hFTH BBa_K1993031
CXCR4-T2A-Luciferase BBa_K1993032
CXCR5-T2A-Luciferase BBa_K1993033